Viola W. Zhu

Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul, Benjamin Besse et autres

us, fr, nl (code pays fourni par la source)

Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.

Sanjay Popat, Benjamin Solomon, Tom Stinchcombe, Geoffrey Liu et autres

gb, au, us, ca (code pays fourni par la source)

Data from NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia et autres

Supplementary Figures S1-S17 from NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia et autres

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia et autres

us, fr, es, kr (code pays fourni par la source)

1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours

B. Besse, Alexander Drilon, BC Cho, D. Ross Camidge et autres

fr, us, kr, tw, au, es, nl (code pays fourni par la source)

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, Yun Fan et autres

tw, kr, cn, it, jp, mx, fr, es, us (code pays fourni par la source)

Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study

G. Mazzoli, Federico Nichetti, Kohei Shitara, Romain Cohen et autres

it, jp, fr, es, us (code pays fourni par la source)

Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors

Melissa L. Johnson, Enriqueta Felip, Sai‐Hong Ignatius Ou, Benjamin Besse et autres

us, es, fr, gb, ca (code pays fourni par la source)

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Vivek Subbiah, Mimi I. Hu, Aaron S. Mansfield, Matthew H. Taylor et autres

us, de, fr, it, es, kr, tw, ch, gb (code pays fourni par la source)

Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira et autres

Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira et autres